Top Left Logo
Cancer Care Health Care Professionals Healthy People, Healthy Communities
Skip Navigation Links
For Health Professionals
Contact Us

Spacer Spacer Spacer Spacer
Index      Small Text Medium Text Large Text  

Literature Support

  1. Gail MH, Constantino JP, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91(21):1829-1846.
  2. Gail MH, Brinton LA, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886.
  3. Brekelmans CTM, Seynaeve C, et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol. 2001;19(4):924-930.
  4. Peshkin BN, DeMarco TA, et al. BRCA1/2 testing: complex themes in result interpertation. J Clin Oncol. 2001;19(9):2555-2565.
  5. Robson M, Gilewski T, et al. BRCA-associated breast cancer in young women. J Clin Oncol. 1998;16(5):1642-1649.
  6. Pharoah PDP, Guilford P, et al. Incidence of gastric cancer and breast cancer in CDH1 (E-Cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121:1348-1353.
  7. Oliveira C, Bordin MC, et al. Screening E-Cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Human Mutation. 2002;19:510-517.
  8. Brooks-Wilson AR, Kaurah P, et al. Germline E-Cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet. 2004;41:508-517.
  9. Suriano G, Yew S, et al. Characterization of a recurrent germ line mutation of the E-Cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res. 2005;11(15):5401-5409.
  10. Kaurah P, MacMillan A, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA. 2007;297(21):2360-2372.
  11. Norton JA, Ham CM, et al. CDH1 truncating mutations in the E-Cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg. 2007;245(6):873-879.
  12. Goss PE, Ingle JN, et al. Exemestane for breast-cancer prevention in postmenopausal women. New Eng J Med. 2011;364(25):2381-2391.
  13. Powles TJ, Jones AL, et al. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Research and Treatment. 1994;31:73-82.
  14. Powles TJ, Ashley S, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99(4):283-290.
  15. Veronesi U, Maisonneuve P, et al. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Lancet. 1998;352(9122):93.
  16. Veronesi U, Maisonneuve P, et al. Tamoxifen for the prevention of breast cancer: Late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy. J Natl Cancer Inst. 2007;99(9):727-737.
  17. IBIS Investigators. First studies from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. Lancet. 2002;360:817-824.
  18. Cuzick J, Forbes JF, et al. Long-term results of tamoxifen prophylaxis for breast cancer – 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99(4):272-282.
  19. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
  20. Vogel VG, Constantino JP, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727-2741.
  21. Vogel VG, Costantino JP, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of tamoxifen and reloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res. 2010;3(6):696-706.
  22. Levine M, Moutquin JM, et al. Chemoprevention of breast cancer: a joint guideline from the Canadian Task Force on preventative health care and the Canadian Breast Cancer Initiative’s Steering
  23. Committee on clinical practice guidelines for the care and treatment of breast cancer. CMAJ. 2001;164(12):1681-1690.
  24. U.S. Preventive Services Task Force. Chemoprevention of breast cancer: Recommendations and rationale. Ann Intern Med. 2002;137(1):56-58.
  25. Kinsinger LS, Harris R, et al. Chemoprevention of breast cancer: A summary of the evidence for the U.S. Preventative Services Task Force. Ann Intern Med. 2002;137(1):59-69.
  26. National Institute for Health and Clinical Excellence. Familial breast cancer: The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. October 2006.
  27. National Hereditary Cancer Task Force. Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. J Obstet Gynaecol Can. 2007;29(1):45-60.
  28. Agency for Healthcare Research and Quality. Comparative effectiveness review No.17: Comparative effectiveness of medications to reduce risk of primary breast cancer in women. 2009.
  29. American College of Physicians. In the clinic: breast cancer screening and prevention. Ann Int Med. 2010;152(7):ITC1-16.
  30. American Cancer Society. Opportunities and strategies for breast cancer prevention through risk reduction. CA Cancer J Clin. 2008;58(6):347-341.
  31. Visvanathan K, Chlebowski RT, et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009;27(19):3235-3258.
  32. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Breast cancer risk reduction. January 2011.
  33. Alberta Health Services. Clinical Practice Guideline BR-011: Risk reduction and surveillance strategies for individuals at high genetic risk for breast and ovarian cancer. April 2011.
  34. Cuzick J, DeCensi A, et al. Preventive therapy for breast cancer: a consensus statement. Lancet. May 2011; 12:496-503.
  35. Brouwers M, Kho ME, et al for the AGREE Next Steps Consortium. AGREE II: Advancing guideline development, reporting and evaluation in healthcare. Can Med J. 2010.doi : 10.1503/cmaj.090449
  36. Brouwers M, Browman G, et al. Guideline adaptation: Enhancing efficiency in guideline development and utilization.



Updated Jul 12, 2012